Little did I realize a few grapes could send my blood sugar soaring until I tried the first glucose monitor without a ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...

New continuous glucose monitoring sensors (small sensors that penetrate the skin to measure glucose levels in real time) are ...

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...

Dexcom‘s Stelo glucose monitor is for those people and I’ve found it works pretty well. It’s available today as the first blood sugar monitor for people who don’t have diabetes yet ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

Dexcom announced today that its G6 continuous glucose monitor (CGM) is being worn by astronauts as part of the Polaris Dawn ...

The FDA cleared Dexcom's Stelo in March. Abbott followed in June, collecting FDA clearances for two separate continuous glucose monitoring systems, the Libre Rio and the Lingo. While the Libre Rio ...